From the Editors

The September issue of The Oncology Nurse-APN/PA (TON) is filled with important news and updates for oncology nurses.

In the August issue of The Oncology Pharmacist (TOP), we feature results of a clinical trial presented at the 2018 American Association for Cancer Research meeting, which showed that the addition of the immune checkpoint inhibitor pembrolizumab to chemotherapy yielded significantly longer overall survival and progression-free survival compared with chemotherapy alone in patients with newly diagnosed metastatic nonsquamous non–small-cell lung cancer.

The July issue of The Oncology Nurse-APN/PA (TON) is packed with indispensable news and insights for today’s oncology nurse.

In this issue, we feature a profile of the Taussig Cancer Center, Cleveland Clinic, OH, where, in my capacity as a nurse practitioner in the Department of Hematologic Oncology and Blood Disorders, my primary role is to diagnose and manage patients with multiple myeloma, amyloidosis, and other hematologic disorders.

The November issue of The Oncology Nurse-APN/PA (TON) is full of important news and updates for oncology nurses.

Results from another clinical trial, ALEX, were also presented at the meeting, and led to alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, being hailed as a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer.

Here's what you can expect to find in the August issue of The Oncology Pharmacist.
Here is what you can expect to read in the July issue of The Oncology Nurse-APN/PA.
The May issue of The Oncology Nurse-APN/PA (TON) is full of important news and updates for oncology nurses
In the May issue of The Oncology Pharmacist (TOP), we feature a conversation with Patrick J. Medina, PharmD, BCOP, Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa, in which he discusses changes to the reimbursement model, bridging the knowledge gap in a rapidly evolving field, and why provider status is the “holy grail” of pharmacy.
Page 1 of 7
Results 1 - 10 of 62